Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
07/2010
07/06/2010US7749718 Method for raising or isolating an antibody to DCRS5
07/06/2010US7749542 For preventing oral abuse of an oral opioid formulation; provides a negative, "aversive" experience when a large amount of the opioid, e.g., about 2-3 times the usually prescribed dose, is taken by or administered to a physically dependent subject
07/06/2010US7749540 Compositions comprising modafinil compounds
07/06/2010US7749515 Therapy or prevention of headaches; administering neurotoxin by injection
07/06/2010US7749514 Activatable clostridial toxins
07/06/2010US7748379 Methods and apparatus for relieving headaches, rhinitis and other common ailments
07/06/2010CA2587792C Therapeutic compositions for intranasal administration of ketorolac
07/06/2010CA2461199C Atlastin
07/06/2010CA2454863C Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
07/06/2010CA2446149C Vitamin d analogues
07/06/2010CA2427429C Acylaminoalkyl-substituted benzenesulfonamide derivatives,their preparation, their use and pharmaceutical preparations comprising them
07/06/2010CA2397497C Process for the preparation of 5-carboxyphthalide and its use for the production of citalopram
07/06/2010CA2370814C Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
07/06/2010CA2369393C High purity (1r,2s,4r)-(-)-2-[(2'-{n,n-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds as well as medicaments containing 1 or more of these compounds and their use
07/01/2010WO2010075263A2 Compounds and methods for enhancing erythropoiesis
07/01/2010WO2010075255A2 Methods for treating or preventing cancer and neurodegenerative diseases
07/01/2010WO2010075204A2 Gamma secretase modulators
07/01/2010WO2010075203A1 Gamma secretase modulators
07/01/2010WO2010075069A1 Bicyclic pyranone derivatives as nicotinic acid receptor agonists
07/01/2010WO2010075064A1 Triple reuptake inhibitors and methods of their use
07/01/2010WO2010074947A1 Amino pyrazole compound
07/01/2010WO2010074753A1 Inhalation devices and related methods for administration of sedative hypnotic compounds
07/01/2010WO2010074647A1 Ethanamine compounds and their use for treating depression
07/01/2010WO2010074607A2 Active substance and pharmaceutical composition for treating alcohol dependence, and a method for obtaining and the use of said active substance
07/01/2010WO2010074591A1 Creatine amides, a method for the production thereof and an agent exhibiting a neuroprotective action
07/01/2010WO2010074480A2 Novel pyrazolodiazepine compounds as a transglutaminase inhibitor, the preparation method thereof and a composition containing the same
07/01/2010WO2010074284A1 Pyrazolopyrimidine compound
07/01/2010WO2010074193A1 Novel bicyclic heterocyclic compound
07/01/2010WO2010073255A1 Process for preparing ziprasidone
07/01/2010WO2010073235A1 Ppar agonist compositions and methods of use
07/01/2010WO2010073104A2 Improving cognitive function
07/01/2010WO2010072807A2 Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide
07/01/2010WO2010072797A1 Compounds and methods for the treatment of autoimmune and inflammatory disease
07/01/2010WO2010072774A2 Agent for treating stenosis of the spinal canal
07/01/2010WO2010072722A1 Piperidine derivatives useful as orexin antagonists
07/01/2010WO2010072610A1 One-step process for preparing paliperidone and its oxalate salt
07/01/2010WO2010072399A1 7-azaindirubins, 7'azaindirubins, 7,7'-diazaindirubins and the corresponding 3'-oxime ether derivatives thereof, their production and use as a medicament
07/01/2010WO2010072352A1 1, 2, 4 -oxadiazole derivatives and their therapeutic use
07/01/2010WO2010072144A1 Substituted phenylpiperazinyl aralkylalcohol derivatives, pharmaceutical compositions containing such derivatives and uses thereof
07/01/2010WO2010072105A1 A enteric formulation of duloxetine and its core and prepration method
07/01/2010WO2010071944A1 Quinazolinone compounds
07/01/2010WO2010054024A3 1, 2 -thiazol yl derivatives as cannabinoid receptor ligands
07/01/2010WO2010030653A3 Nurr1 interacting protein (nuip)
07/01/2010WO2010028207A9 Method of treatment of attention deficit/hyperactivity disorder (adhd)
07/01/2010WO2010024927A3 Treatment of amyloidoses using myelin basic protein and fragments thereof
07/01/2010WO2010016043A8 Treatment of retinal degeneration
07/01/2010WO2009114097A3 Method of modulating t cell-dependent immune responses
07/01/2010WO2009059239A3 REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
07/01/2010US20100169994 Animal model
07/01/2010US20100168720 System for providing fluid flow to nerve tissues
07/01/2010US20100168448 Methods of Preparing Cannabinoids From Plant Material
07/01/2010US20100168248 Process for producing enriched fractions of tetrahydroxycurcumin and tetrahydrotetrahdroxy-curcumin from the extracts of curcuma longa
07/01/2010US20100168246 Amine compounds and inhibiting neurotransmitter reuptake
07/01/2010US20100168244 Naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them
07/01/2010US20100168239 Use of Rasagiline for the Treatment of Multiple System Atrophy
07/01/2010US20100168229 Process for the preparation of optically active compounds using transfer hydrogenation
07/01/2010US20100168208 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)
07/01/2010US20100168199 Kinase Inhibitors
07/01/2010US20100168196 N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them
07/01/2010US20100168195 Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
07/01/2010US20100168194 Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone Compounds For The Inhibition Of Beta-secretase
07/01/2010US20100168193 Therapeutic use of imidazole-5-carboxylic acid derivatives
07/01/2010US20100168192 Benzisoxazole derivatives as potassium channel modulators for the treatment of e.g. respiratory diseases, epilepsy and convulsions
07/01/2010US20100168191 Pharmaceutical formulation comprising pramipexole
07/01/2010US20100168188 Estrogen Receptor Modulators
07/01/2010US20100168174 Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain
07/01/2010US20100168171 Piperidinone Carboxamide Derivatives as P2X7 Modulators
07/01/2010US20100168170 Piperidinones Useful in the Treatment of Inflammation
07/01/2010US20100168168 Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands
07/01/2010US20100168165 Method of treating disease involving myelin and/or axonal loss
07/01/2010US20100168158 Modulators of cystic fibrosis transmembrane conductance regulator
07/01/2010US20100168156 Novel Benzoxathiine Derivative
07/01/2010US20100168155 DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS
07/01/2010US20100168154 1-substituted tetrahydroisoquinoline compound
07/01/2010US20100168153 Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
07/01/2010US20100168148 Pharmaceutical formulation containing gelling agent
07/01/2010US20100168147 Medicinal Compositions Comprising Buprenorphine And Naloxone
07/01/2010US20100168146 Composition Comprising (R)-Spiro[L-Azabicyclo[2.2.2]Octane-3,2'(3'H)-Furo[2,3-B]Pyridine (AZD0328) and its Use in the Treatment of Alzheimer's Disease, ADHD or Cognitive Dysfunction
07/01/2010US20100168144 Inhibitors of protein kinases
07/01/2010US20100168139 Inhibitors of human phosphatidylinositol 3-kinase delta
07/01/2010US20100168137 Combination for use in the treatment of inflammatory disorders
07/01/2010US20100168136 Alkylsulfone derivatives
07/01/2010US20100168134 Pyridyl piperidine orexin receptor antagonists
07/01/2010US20100168131 Novel compounds
07/01/2010US20100168130 Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof
07/01/2010US20100168125 Indolizines and aza-analog derivatives thereof as cns active compounds
07/01/2010US20100168113 Pharmaceutical Compounds
07/01/2010US20100168110 Novel Compounds
07/01/2010US20100168109 Pharmaceutical compositions of 1,2,4-oxadiazole benzoic acid and their use for the treatment of disease
07/01/2010US20100168107 Imidazole compounds for the treatment of neurodegenerative disorders
07/01/2010US20100168106 Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation
07/01/2010US20100168105 Spirocyclopropyl Piperidine Derivatives
07/01/2010US20100168103 Diaryl piperidine compounds as calcium channel blockers
07/01/2010US20100168102 Amide Derivatives as Kinase Inhibitors
07/01/2010US20100168099 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions
07/01/2010US20100168094 Modulators of cystic fibrosis transmembrane conductance regulator
07/01/2010US20100168093 Substituted 3-amino-4 -hydroxy pyrrolidines compounds, their preparation and use as medicaments
07/01/2010US20100168091 Imidazole Amines As Inhibitors Of Beta-secretase
07/01/2010US20100168088 Pyrrolidine derivatives as nk-3 receptor antagonists
07/01/2010US20100168087 Benzo[1,2,3]thiadiazine derivates
1 ... 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 ... 1833